U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19NO4.ClH.H2O
Molecular Weight 355.813
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYMORPHONE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@]3(O)CCC4=O)=CC=C5O

InChI

InChIKey=VLPORDTVKOPOLC-YNLRGPPVSA-N
InChI=1S/C17H19NO4.ClH.H2O/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9;;/h2-3,12,15,19,21H,4-8H2,1H3;1H;1H2/t12-,15+,16+,17-;;/m1../s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H19NO4
Molecular Weight 301.3371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf | https://www.drugs.com/pro/oxymorphone.html

Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.

CNS Activity

Originator

Weiss, U.
5
Sources: DOI:10.1021/ja01627a033

Approval Year

1959
143
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 0.93 nM [Ki]
Agonist
2752
 80.5 nM [Ki]
Agonist
2752
 61.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

1959
Palliative
Approved
8583
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.27 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.21 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.59 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.7 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.54 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.47 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.54 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.81 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
37.9 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
5.6 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
19.28 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
36.98 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.89 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
9.35 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (mild, 4.3%)
Nausea (4.3%)
Dizziness (4.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Disc. AE: Abdominal pain, Chest pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.4%)
Chest pain (1.4%)
Serum creatine phosphokinase increased (1.4%)
Serum creatine phosphokinase MB increased (1.4%)
Back pain (1.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Disc. AE: Opioid abuse, Addiction...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Addiction
Respiratory depression (grade 3-5)
Withdrawal syndrome neonatal
Anaphylaxis
Hypotension (severe)
Angioedema
Hypersensitivity reaction
Adrenal insufficiency
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Dizziness 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
Nausea 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
Vomiting mild, 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15777102
Abdominal pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Back pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Chest pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Serum creatine phosphokinase MB increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Serum creatine phosphokinase increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15629415
Addiction Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Opioid abuse Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Respiratory depression Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Hypotension severe
Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Addiction Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Opioid abuse Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Respiratory depression Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Hypotension severe
Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf
Addiction Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Adrenal insufficiency Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Anaphylaxis Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Angioedema Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Hypersensitivity reaction Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Opioid abuse Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Withdrawal syndrome neonatal Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Respiratory depression grade 3-5
Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Hypotension severe
Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
1087
inducer
440

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP 450
20
CYP 450
32
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP 450
22
 no
CYP2C9
2497
 no
CYP3A4
2633
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP 450
32
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
AHH Chemical co.,ltd
MT-57608
http://www.ahhchemical.com/product/MT-57608.html
Alsachim
4226
http://www.alsachim.com/product-C5544-glo.bal-view.html
Ambinter
Amb22801505
http://www.ambinter.com/reference/22801505
Aurora Fine Chemicals LLC
A17.921.625
http://online.aurorafinechemicals.com/info?ID=A17.921.625
Avantor Inc
75835-940
https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
BioCrick
BCC5255
http://www.biocrick.com/Oxymorphone-BCC5255.html
Chem Scene
CS-2852
http://www.chemscene.com/Oxymorphone.html
ChemMol
30105081
http://www.chemmol.com/chemmol/30105081.html
LGC Standards
LGCAMP0673.01-01
https://www.lgcstandards.com/US/en/p/LGCAMP0673.01-01
LGC Standards
LGCAMP0673.01-02
https://www.lgcstandards.com/US/en/p/LGCAMP0673.01-02
MedChem Express
HY-B0618
http://www.medchemexpress.com/Oxymorphone.html
Sigma-Aldrich
O-004_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/o004?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S619016
https://www.smolecule.com/products/s619016
PubMed

PubMed

TitleDatePubMed
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
2008-03
Comment: Oral oxymorphone for pain management.
2007-12
Determination of opioid analgesics in hair samples using liquid chromatography/tandem mass spectrometry and application to patients under palliative care.
2007-10
Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry.
2007-09
Rapid analysis of metabolites and drugs of abuse from urine samples by desorption electrospray ionization-mass spectrometry.
2007-09
GC-MS analysis of multiply derivatized opioids in urine.
2007-08
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
2007-07-02
Oral extended-release oxymorphone: a new choice for chronic pain relief.
2007-07
Oral oxymorphone for pain management.
2007-07
Nociception increases during opioid infusion in opioid receptor triple knock-out mice.
2007-06-29
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
2007-06
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base.
2007-05-30
Use of oral oxymorphone in the elderly.
2007-05
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
2007-04-01
Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis.
2007-03-23
Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
2007-03-08
Oxymorphone hydrochloride, a potent opioid analgesic, is not carcinogenic in rats or mice.
2007-03
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.
2007-02
Extended-duration agents for perioperative pain management.
2007-02
Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.
2007-02
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
2007-02
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia.
2007-02
The effect of opiates on the activity of human placental aromatase/CYP19.
2007-01-15
Oral oxymorphone (Opana).
2007-01-01
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
2007-01
New pain management options: drugs.
2007-01
Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites.
2006-10
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
2006-10
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization.
2006-07
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.
2006-06-05
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
2006-05
An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites.
2006-05
Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.
2006-04-04
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery.
2006-03-20
Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain.
2006-03-04
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
2006-03
Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory.
2006-03
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
2006-03
Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
2006-02-16
Oxymorphone: a review.
2006-02
Effects of oxymorphone and hydromorphone on the minimum alveolar concentration of isoflurane in dogs.
2006-01
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
2006
Dissociative anaesthesia during field and hospital conditions for castration of colts.
2006
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial.
2005-12
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
2005-11-04
Direct analysis of opiates in urine by liquid chromatography-tandem mass spectrometry.
2005-10
Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine.
2005-10
Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
2005-09
Evaluation of induction by use of a combination of oxymorphone and diazepam or hydromorphone and diazepam and maintenance of anesthesia by use of isoflurane in dogs with experimentally induced hypovolemia.
2005-07
Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.
2005
Patents

Patents

JP2002541233A
406
JP2011527310A
12
JP2011529490A
17
JP4790415B2
14
JP4800219B2
66

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf
Subcutaneous or Intramuscular administration: Initiate treatment with 1mg to 1.5 mg, every 4 to 6 hours. Intravenous Administration: 0.5 mg initially Oral: 10 to 20 mg every four to six hours.
Route of Administration: Other
In Vitro Use Guide
Oxymorphone hydrochloride was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test) at concentrations of ≤5270 ug/plate, or in an in vitro mammalian cell chromosome aberration assay performed with human peripheral blood lymphocytes at concentrations ≤5000 ug/mL with or without metabolic activation.
Substance Class Chemical
Created
by admin
on Tue Apr 01 16:26:38 GMT 2025
Edited
by admin
on Tue Apr 01 16:26:38 GMT 2025
Record UNII
CV52YZ5G1X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYMORPHONE HYDROCHLORIDE MONOHYDRATE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-, HYDRCHLORIDE, HYDRATE (1:1:1), (5.ALPHA.)-
Preferred Name English
Code System Code Type Description
CAS
1415015-79-0
Created by admin on Tue Apr 01 16:26:38 GMT 2025 , Edited by admin on Tue Apr 01 16:26:38 GMT 2025
PRIMARY
CAS
1033330-03-8
Created by admin on Tue Apr 01 16:26:38 GMT 2025 , Edited by admin on Tue Apr 01 16:26:38 GMT 2025
NON-SPECIFIC STOICHIOMETRY
PUBCHEM
68792735
Created by admin on Tue Apr 01 16:26:38 GMT 2025 , Edited by admin on Tue Apr 01 16:26:38 GMT 2025
PRIMARY
FDA UNII
CV52YZ5G1X
Created by admin on Tue Apr 01 16:26:38 GMT 2025 , Edited by admin on Tue Apr 01 16:26:38 GMT 2025
PRIMARY
Related Record Type Details
Structure of OXYMORPHONE HYDROCHLORIDE
ANHYDROUS->SOLVATE
Structure of OXYMORPHONE
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966